We know that both allogeneic stem cell transplant and autologous transplantation are curative treatment strategies for many patients with hematological malignancies, but we still have a significant proportion of patients that relapse after transplantation or eventually die because of complications related to the procedure. In this sense, there is a clear need, in spite of all the information that we have been gathering over the last few years, to try to better identify prognostic groups of patients that will have higher relapse rate or that will have higher chances to die from the procedure...
We know that both allogeneic stem cell transplant and autologous transplantation are curative treatment strategies for many patients with hematological malignancies, but we still have a significant proportion of patients that relapse after transplantation or eventually die because of complications related to the procedure. In this sense, there is a clear need, in spite of all the information that we have been gathering over the last few years, to try to better identify prognostic groups of patients that will have higher relapse rate or that will have higher chances to die from the procedure. All this information and prognostic factors can be better done with the use of big data. So, in this sense, big data will allow us to better personalize the transplantation procedure in our patients.
